Sector News

Canada’s Valeant to buy Salix in $10.1 billion deal

February 23, 2015
Life sciences
(Reuters) – Canada’s Valeant Pharmaceuticals International Inc agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday.
 
The deal for Salix, known for its irritable bowel syndrome drug Xifaxan, was approved by the boards of directors of both companies, the companies said in a news release.
 
The companies said the deal had an enterprise value of $14.5 billion, which would include Salix’s debt and any cash on hand. Valeant will pay $158.00 a share, valuing the all-cash transaction at about $10.1 billion.
 
The merger is expected to yield more than $500 million in annual cost savings within six months, the release said.
 
The transaction is expected to close in the second quarter of 2015, and is subject to customary closing conditions and regulatory approval.
 
The deal is the largest ever for Laval, Quebec-based Valeant, which lost a takeover contest for Allergan Inc (AGN.N) last year. The usually acquisitive Valeant slowed its buying pace dramatically while it pursued Allergan, and Chief Executive Michael Pearson said last month that it would focus on buying smaller, private companies in 2015.
 
Pearson said in the release that Salix, based in Raleigh, North Carolina, was an “ideal strategic fit” for Valeant.
 
The failure to acquire Botox-maker Allergan led Valeant to reassess its history of growth by acquisition and to target a higher stock price and debt-reduction in the next two to three quarters, people familiar with the matter told Reuters in December.
 
Valeant said on Sunday it had reduced long-term debt to $15.3 billion at the end of December, from $17.2 billion at the end of 2013.
 
Valeant also released its fourth-quarter results with the announcement, posting net income of $534.1 million, or $1.56 per diluted share, compared to $125.0 million in the year-earlier period, or 36 cents per diluted share.
 
Revenue rose to $2.28 billion, up from $2.06 billion in the fourth quarter of 2013.
 
Valeant said it expects cash earnings of $2.30 per share in this year’s first quarter.
 
British drugmaker Shire Plc as of last week had taken initial steps to acquire Salix and was working with advisers on a potential offer, according to people familiar with the matter.
 
Endo International Plc had expressed interest but was rebuffed by Salix, according to a source.
 
CNBC first reported on Friday that Valeant was close to a deal with Salix.
 
Sullivan & Cromwell LLP served as Valeant’s legal counsel, and Salix was advised by Cadwalader, Wickersham & Taft LLP.
 
(Reporting by Herbert Lash; Editing by Frances Kerry and Tom Brown)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.